NO20030137L - Fremgangsmåte for behandling av ustabil angina pectoris - Google Patents

Fremgangsmåte for behandling av ustabil angina pectoris

Info

Publication number
NO20030137L
NO20030137L NO20030137A NO20030137A NO20030137L NO 20030137 L NO20030137 L NO 20030137L NO 20030137 A NO20030137 A NO 20030137A NO 20030137 A NO20030137 A NO 20030137A NO 20030137 L NO20030137 L NO 20030137L
Authority
NO
Norway
Prior art keywords
angina pectoris
unstable angina
procedure
treatment
hypercholesterolaemia
Prior art date
Application number
NO20030137A
Other languages
English (en)
Other versions
NO20030137D0 (no
NO329848B1 (no
Inventor
Thomas F Luescher
Georg Noll
Peter Lerch
Original Assignee
Zlb Bioplasma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zlb Bioplasma Ag filed Critical Zlb Bioplasma Ag
Publication of NO20030137D0 publication Critical patent/NO20030137D0/no
Publication of NO20030137L publication Critical patent/NO20030137L/no
Publication of NO329848B1 publication Critical patent/NO329848B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Supports For Pipes And Cables (AREA)
  • External Artificial Organs (AREA)
NO20030137A 2000-07-20 2003-01-10 Anvendelse av rekonstituert HDL NO329848B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10035352A DE10035352A1 (de) 2000-07-20 2000-07-20 Verfahren zur Behandlung von instabiler Angina pectoris
PCT/EP2001/008425 WO2002007753A2 (de) 2000-07-20 2001-07-20 Verfahren zur behandlung von instabiler angina pectoris

Publications (3)

Publication Number Publication Date
NO20030137D0 NO20030137D0 (no) 2003-01-10
NO20030137L true NO20030137L (no) 2003-01-10
NO329848B1 NO329848B1 (no) 2011-01-10

Family

ID=7649620

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030137A NO329848B1 (no) 2000-07-20 2003-01-10 Anvendelse av rekonstituert HDL

Country Status (17)

Country Link
US (1) US7053049B2 (no)
EP (1) EP1303294B1 (no)
JP (1) JP4928047B2 (no)
KR (2) KR100864079B1 (no)
AT (1) ATE333887T1 (no)
AU (2) AU8200401A (no)
CA (1) CA2418238C (no)
DE (2) DE10035352A1 (no)
DK (1) DK1303294T3 (no)
ES (1) ES2266234T3 (no)
HU (1) HU230151B1 (no)
IL (2) IL154006A0 (no)
NO (1) NO329848B1 (no)
NZ (1) NZ523784A (no)
PL (1) PL204406B1 (no)
WO (1) WO2002007753A2 (no)
ZA (1) ZA200300509B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US7956035B2 (en) * 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
EP2900475B1 (en) 2012-09-25 2018-03-28 Hewlett-Packard Development Company, L.P. Drop detection
ITMI20131300A1 (it) * 2013-08-01 2015-02-02 Nobil Bio Ricerche Srl Composizione per il riempimento di difetti ossei e parodontali
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
GB2603950B (en) 2021-02-22 2025-04-23 Reckitt & Colman Overseas Hygiene Home Ltd Effervescent germicidal compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
CA2124086A1 (en) * 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
JPH10218861A (ja) * 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AU777788B2 (en) * 1999-11-26 2004-10-28 Heart Research Institute Limited, The Oxidized apolipoproteins and methods of use
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
ES2266234T3 (es) 2007-03-01
AU8200401A (en) 2002-02-05
KR100864079B1 (ko) 2008-10-16
IL154006A (en) 2010-05-31
CA2418238A1 (en) 2003-01-16
IL154006A0 (en) 2003-07-31
DK1303294T3 (da) 2006-10-30
HUP0300730A3 (en) 2010-07-28
NZ523784A (en) 2004-06-25
HU230151B1 (hu) 2015-09-28
WO2002007753A3 (de) 2003-02-13
EP1303294A2 (de) 2003-04-23
ZA200300509B (en) 2004-02-17
NO20030137D0 (no) 2003-01-10
AU2001282004B2 (en) 2006-02-02
US20040014654A1 (en) 2004-01-22
US7053049B2 (en) 2006-05-30
DE10035352A1 (de) 2002-01-31
PL204406B1 (pl) 2010-01-29
CA2418238C (en) 2012-06-05
NO329848B1 (no) 2011-01-10
PL366395A1 (en) 2005-01-24
JP4928047B2 (ja) 2012-05-09
EP1303294B1 (de) 2006-07-26
KR20070108955A (ko) 2007-11-13
HUP0300730A2 (hu) 2003-12-29
WO2002007753A2 (de) 2002-01-31
KR20030026980A (ko) 2003-04-03
DE50110552D1 (de) 2006-09-07
ATE333887T1 (de) 2006-08-15
JP2004504355A (ja) 2004-02-12

Similar Documents

Publication Publication Date Title
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
MEP26808A (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
NO20034056D0 (no) Proliferative sykdommer
NO20021830L (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
BR9913564A (pt) Tratamento de angiopatias microvasculares
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
NO20030137D0 (no) Fremgangsmåte for behandling av ustabil angina pectoris
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
WO2002083700A3 (en) Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
DE60011601D1 (de) Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
DE60134885D1 (de) Antiangiogene polypeptide
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
PT1207899E (pt) Tratamento da rinite alergica com certas proteinas de ligacao de aminas vasoactivas
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
BR0013665A (pt) Uso de uma proteìna histacalina, composição farmacêutica, e, método de tratar ou impedir conjuntivite
LU91009B1 (de) Behandlung von Verbrennungen
LT2002131A (en) New use of fir oil for cosmetic
DE60043936D1 (de) Vorbeugung und behandlung von p. gingivalis infektion

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees